questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Inhibiteurs de prolyle hydroxylases
Inhibiteurs de prolyle hydroxylases : Questions médicales fréquentes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de prolyle hydroxylases : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de prolyle hydroxylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de prolyle hydroxylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-14",
"dateModified": "2025-02-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antienzymes",
"url": "https://questionsmedicales.fr/mesh/D004791",
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases",
"alternateName": "Prolyl-Hydroxylase Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D064800",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christopher J Schofield",
"url": "https://questionsmedicales.fr/author/Christopher%20J%20Schofield",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry , University of Oxford , Chemistry Research Laboratory , 12 Mansfield Road , Oxford , OX1 3TA , UK . Email: christopher.schofield@chem.ox.ac.uk."
}
},
{
"@type": "Person",
"name": "Anthony Tumber",
"url": "https://questionsmedicales.fr/author/Anthony%20Tumber",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry , University of Oxford , Chemistry Research Laboratory , 12 Mansfield Road , Oxford , OX1 3TA , UK . Email: christopher.schofield@chem.ox.ac.uk."
}
},
{
"@type": "Person",
"name": "Tetsuhiro Tanaka",
"url": "https://questionsmedicales.fr/author/Tetsuhiro%20Tanaka",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine."
}
},
{
"@type": "Person",
"name": "Masaomi Nangaku",
"url": "https://questionsmedicales.fr/author/Masaomi%20Nangaku",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine."
}
},
{
"@type": "Person",
"name": "Martine I Abboud",
"url": "https://questionsmedicales.fr/author/Martine%20I%20Abboud",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Oxford, Oxford, OX1 3TA, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A case report of dipeptidyl peptidase 4 inhibitor-related kidney disease combined with renal cancer.",
"datePublished": "2024-07-29",
"url": "https://questionsmedicales.fr/article/39135967",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fneph.2024.1409098"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39118889",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21037/tlcr-24-372"
}
},
{
"@type": "ScholarlyArticle",
"name": "Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity.",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39067715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bmcl.2024.129911"
}
},
{
"@type": "ScholarlyArticle",
"name": "Inhibition of human DNA alkylation damage repair enzyme ALKBH2 by HIV protease inhibitor ritonavir.",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39094381",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.dnarep.2024.103732"
}
},
{
"@type": "ScholarlyArticle",
"name": "PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients.",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39170496",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.heliyon.2024.e34937"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inhibiteurs de prolyle hydroxylases",
"item": "https://questionsmedicales.fr/mesh/D064800"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de prolyle hydroxylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de prolyle hydroxylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment diagnostiquer une carence en oxygène ?\nQuels tests sont utilisés pour évaluer l'efficacité des inhibiteurs ?\nQuels symptômes indiquent un besoin d'inhibiteurs ?\nComment évaluer l'anémie liée à l'hypoxie ?\nQuels marqueurs biologiques sont pertinents ?",
"url": "https://questionsmedicales.fr/mesh/D064800?page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de prolyle hydroxylases",
"description": "Quels sont les symptômes d'une hypoxie ?\nComment se manifeste l'anémie ?\nQuels signes indiquent une amélioration avec les inhibiteurs ?\nLes inhibiteurs affectent-ils l'appétit ?\nQuels symptômes peuvent aggraver l'état ?",
"url": "https://questionsmedicales.fr/mesh/D064800?page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment prévenir l'hypoxie chez les patients à risque ?\nQuels modes de vie favorisent une bonne oxygénation ?\nLes vaccinations aident-elles à prévenir l'hypoxie ?\nComment éviter les complications liées à l'anémie ?\nLes contrôles réguliers sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D064800?page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment fonctionnent les inhibiteurs de prolyle hydroxylases ?\nQuels sont les effets secondaires des inhibiteurs ?\nLes inhibiteurs sont-ils utilisés en monothérapie ?\nQuelle est la durée du traitement avec ces inhibiteurs ?\nY a-t-il des alternatives aux inhibiteurs ?",
"url": "https://questionsmedicales.fr/mesh/D064800?page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de prolyle hydroxylases",
"description": "Quelles complications peuvent survenir avec l'hypoxie ?\nLes inhibiteurs peuvent-ils causer des complications ?\nComment gérer les complications liées à l'anémie ?\nQuels sont les risques d'une surdose d'inhibiteurs ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D064800?page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de prolyle hydroxylases",
"description": "Quels facteurs augmentent le risque d'hypoxie ?\nL'âge influence-t-il le risque d'anémie ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie affecte-t-il le risque d'hypoxie ?\nLes conditions environnementales influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D064800?page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en oxygène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie peuvent évaluer l'oxygénation."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des inhibiteurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de fonction pulmonaire et des dosages d'érythropoïétine sont courants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'inhibiteurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, essoufflement et pâleur peuvent signaler une hypoxie nécessitant un traitement."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'anémie liée à l'hypoxie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un hémogramme et des tests de fer aident à diagnostiquer l'anémie."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont pertinents ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'érythropoïétine et d'hémoglobine sont des marqueurs clés."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hypoxie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, confusion, essoufflement et cyanose."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'anémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'anémie se manifeste par fatigue, pâleur, et parfois des palpitations."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une amélioration avec les inhibiteurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation de l'énergie et une réduction de l'essoufflement sont des signes d'amélioration."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs affectent-ils l'appétit ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains patients peuvent ressentir une amélioration de l'appétit avec un meilleur oxygénation."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent aggraver l'état ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'augmentation de la fatigue et des douleurs thoraciques peuvent aggraver l'état."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypoxie chez les patients à risque ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveiller régulièrement la fonction pulmonaire et traiter les maladies sous-jacentes."
}
},
{
"@type": "Question",
"name": "Quels modes de vie favorisent une bonne oxygénation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et l'arrêt du tabac favorisent l'oxygénation."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles à prévenir l'hypoxie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations contre les infections respiratoires peuvent réduire le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "Comment éviter les complications liées à l'anémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un traitement précoce de l'anémie sont essentiels."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers sont-ils nécessaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter précocement les problèmes d'oxygénation."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les inhibiteurs de prolyle hydroxylases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent l'enzyme prolyle hydroxylase, augmentant ainsi la production d'érythropoïétine."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des inhibiteurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des nausées, des vertiges et des maux de tête."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs sont-ils utilisés en monothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être utilisés seuls ou en association avec d'autres traitements selon le cas."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement avec ces inhibiteurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée dépend de la réponse au traitement et de la gravité de l'hypoxie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives aux inhibiteurs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions sanguines et des suppléments de fer peuvent être des alternatives."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hypoxie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions organiques, des troubles cognitifs et des arythmies."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs peuvent-ils causer des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme l'hypertension et des troubles gastro-intestinaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'anémie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement approprié et un suivi régulier sont essentiels pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une surdose d'inhibiteurs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surdose peut entraîner des effets indésirables graves, nécessitant une attention médicale."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et rapide."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hypoxie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies pulmonaires, le tabagisme et l'obésité augmentent le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anémie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées sont plus susceptibles de développer une anémie."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'anémie ou de maladies respiratoires augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque d'hypoxie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une mauvaise alimentation augmentent le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "Les conditions environnementales influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, vivre en altitude ou dans des zones polluées peut augmenter le risque d'hypoxie."
}
}
]
}
]
}
A kidney biopsy was performed in a 64-year-old woman with type 2 diabetes mellitus and less than 1 g of proteinuria who rapidly progressed to end-stage renal failure after approximately 2 years of tre...
Kirsten rat sarcoma homolog (...
Our retrospective study involved 240 advanced NSCLC patients with...
The median follow-up time was 36.5 months (range, 30.8-42.1 months) and the median OS was 9.7 months (range, 7.6-11.8 months). Of the 240 patients evaluated, 130 (54.2%) received chemotherapy and 110 ...
Despite having potential survival disadvantage compared with other NSCLC patients, rare KRAS-mutant patients (other than G12A, C, D, V) could benefit specifically from ICI-based therapy and survival o...
Bacterial DNA gyrase and topoisomerase IV inhibition has emerged as a promising strategy for the cure of infections caused by antibiotic-resistant bacteria. The Novel Bacterial Topoisomerase Inhibitor...
The human DNA repair enzyme AlkB homologue-2 (ALKBH2) repairs methyl adducts from genomic DNA and is overexpressed in several cancers. However, there are no known inhibitors available for this crucial...
We aimed to demonstrate the function of premelanosome protein (PMEL) as a biomarker to predict the effectiveness of mammalian target of rapamycin complex 1 (mTORC1) inhibitor treatment in renal angiom...
95 whole blood samples from 49 patients diagnosed with TSC-RAMLs were collected. PMEL, N4BP2, and PCSK1N expression in the plasma samples were tested by quantitative sandwich ELISA. The target tumor v...
The tumor size of TSC-RAMLs positivity correlated with PMEL expression (r = 0.30, p = 0.036) and PCSK1N expression (r = 0.23, p = 0.027), but had no significant relationship with N4BP2 (r = 0.06, p = ...
PMEL expression positively correlated with the tumor size of TSC-RAMLs, and inversely with the reduction rate of TSC-RAMLs after mTORC1 inhibitor treatment, which may suggest that PMEL may serve as a ...
This Patent Highlight presents a detailed analysis of three novel classes of compounds designed to inhibit multiple forms of the K-Ras protein, as described in three patent applications. These patents...
No intervention definitively extends transplant-free survival in primary sclerosing cholangitis (PSC). Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), may enhance PSC p...
We analyzed HMGCR single-nucleotide polymorphisms from published genome-wide association studies using Mendelian randomization to assess the causal relationship between HMGCR and PSC risk. Effects of ...
Genetically predicted HMGCR exhibited a pronounced detrimental effect on PSC in both the IVW method (odds ratio [OR] [95%] = 2.43 [1.23-4.78],...
This study has confirmed a causal relationship between HMGCR and PSC risk, suggesting statins targeting HMGCR could enhance PSC patient outcomes....
The resistance of osteosarcoma (OS) to ionizing radiation (IR) is an obstacle for effective patient treatment. Apurinic/apyrimidinic endonuclease-reduction/oxidation factor 1 (APE1/Ref-1) is a multifu...
Abnormal deposition or aggregation of protein alpha-synuclein and tau in the brain leads to neurodegenerative disorders. Excessive hyperphosphorylation of tau protein and aggregations destroys the mic...
The online version contains supplementary material available at 10.1007/s40203-024-00242-z....
Plasmin-induced protein hydrolysis significantly compromises the stability of ultrahigh-temperature (UHT) milk. β-Lactoglobulin (β-Lg) was observed to inhibit plasmin activity, suggesting that there w...